Journal
BIOLOGICAL PSYCHIATRY
Volume 64, Issue 10, Pages 880-883Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2008.06.027
Keywords
Depression; hippocampus; remission; response
Categories
Funding
- Canadian Institutes of Health Research (CIHR)
- Wyeth
- AstraZeneca
- Janssen
- Lilly
- Novartis
- GSK
- Boerhinger
- Oryx
- Lundheck
- CIHR
- Ontario Mental Health Foundation (OMHF)
- National Institutes of Mental Health
- National Alliance for Research on Schizophrenia and Depression (NARSAD)
- Stanley Medical Research Foundation
- Scotish Rite Foundation
- AllerGen
- Society of American Gastrointestinal Endoscopic Surgeons
- Community Health, Education, and Research Fund
- Regional Medical Association
- Center for Minimally Invasive Surgery
- Sanofi-Agentis (Canada)
- Novartis (Canada)
- Eli Lilly Neurosciences Foundation (Canada)
- St. Joseph's Healthcare Foundation
Ask authors/readers for more resources
Background: The hippocampus (HC) is smaller in patients with recurrent major depressive disorder (MDD), but few longitudinal studies have examined whether volume is associated with clinically meaningful outcomes such as response to treatment. Methods: We compared regional (head and body/tail) HC volumes in 46 patients with MDD, 14 of whom remitted after 8 weeks of first treatment to HC volumes of 32 patients who were not in remission after 8 weeks. Results: Patients who remitted had larger pretreatment hippocampal body/tail volumes bilaterally compared with those who were not in remission at 8 weeks. This difference was not apparent in either the right or left hippocampal head. Conclusions: These findings extend a small number of previous reports, suggesting that regional brain volumes might be associated with rate and extent of clinical response to antidepressant medication.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available